Phage Therapy Brazil: Universities vs Superbugs | AcademicJobs
Explore how USP, Unifesp, and Unicamp drive fagoterapia research against superbactérias, from Cepid B3 to KIDNAP Study, amid Brazil's AMR crisis.
No reviews yet. Be the first to rate Ana Cristina!
Ana Cristina Gales, MD, PhD, serves as Professor in the Division of Infectious Diseases at the Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-UNIFESP), where she also directs the Laboratório Alerta. She earned her medical degree from the Faculdade de Medicina do ABC (FMABC) in 1991. She completed residency training in Internal Medicine and Infectious Diseases at EPM-UNIFESP from 1992 to 1995 and obtained a PhD in Health Sciences from EPM-UNIFESP in 2001. Her training included a research fellowship in medical microbiology at the Department of Pathology, University of Iowa, Iowa City, USA, from 1998 to 2000.
Dr. Gales’s research centers on the molecular epidemiology of multidrug-resistant bacteria and the in vitro activity of novel antimicrobial agents. She has authored more than 300 peer-reviewed publications. She is a full member of the Technical Chamber on Microbial Resistance in Health Services (CATREM), advising the Brazilian Health Regulatory Agency (Anvisa). She serves as Vice-Coordinator of the Antimicrobial Resistance Institute of São Paulo (ARIES) and, since June 2025, as Health Area Manager at the São Paulo Research Foundation (FAPESP). She chaired the Brazilian Committee on Antimicrobial Susceptibility Testing (BrCAST) from 2017 to 2018 and serves on the editorial boards of The Brazilian Journal of Infectious Diseases and the Journal of Global Antimicrobial Resistance. She has been a member of the Scientific Advisory Committee of the Global Antibiotic R&D Partnership (GARDP) since 2021 and has contributed to multiple global antimicrobial resistance surveillance programs.
Explore how USP, Unifesp, and Unicamp drive fagoterapia research against superbactérias, from Cepid B3 to KIDNAP Study, amid Brazil's AMR crisis.